In tissue, a similar pattern was also observed as TMA specimens displayed a significant increase of CYP1A1 expression in prostate cancer compared to normal and BPH; and methylation analyses of clinical specimens exhibited cancer to be hypomethylated at all three enhancer sites (XRE-1383, XRE-983, XRE-895) compared to BPH. Here, CYP1A1 is linked to prostate cancer.